

SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: (Check applicable drug below)

tiopronin (Thiola®)

tiopronin delayed-release tablets (Thiola® EC)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight: _____ Date: _____

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- Provider requesting this medication is a nephrologist or has experience in treating/monitoring members with homozygous cystinuria

AND

(Continued on next page)

- Member has a confirmed diagnosis of homozygous cystinuria (**documentation recording family history, history of nephrolithiasis, kidney stone collection analysis, and metabolic testing/24-hour urinalysis MUST accompany request**)

AND

- Before any treatment for cystinuria, the urine cystine levels have been measured to be greater than 500mg/day (**laboratory results MUST be attached to request**)

Laboratory Results: _____ Date of test: _____

AND

- Prevention of recurrent cystine stones in this member has not been achieved with increased fluid intake, restriction of sodium/protein intake, and urinary alkalization (**ALL OF THESE THERAPY TRIALS/FAILURES MUST BE RECORDED, DOCUMENTED AND SUBMITTED WITH THIS REQUEST**)

AND

- A baseline urinary protein level has been measured, and there are **NOT** signs of proteinuria

Laboratory Results: _____ Date of test: _____

AND

- A lower dose will be initiated for members who have experienced severe toxicity with D-Penicillamine

AND

- FOR PEDIATRIC PATIENTS:** Current weight is ≥ 20 kg

Current weight measurement: _____ Date of measurement: _____

(NOTE: tiopronin (Thiola) or tiopronin DR (Thiola EC) will **NOT** be approved for members less than 20kg, or for doses greater than 50mg/kg)

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

NOTE: Renal function, 24-hour urinary protein and urinalysis should have been measured at baseline and then every 3 to 6 months, and urinary cystine level measured 1 month after initiating treatment and then every 3 months thereafter

- Member does **NOT** have signs of proteinuria (**Provide the last interval of urinalysis measuring urinary protein – laboratory results MUST be attached to request**)

Laboratory Results: _____ Date of test: _____

AND

(Continued on next page)

- ❑ Provide the last interval of urinalysis measuring urinary cystine levels (**laboratory results MUST be attached to request**)

Laboratory Results: _____ Date of test: _____

NOTE: Maintenance dose should be adjusted to reduce urinary cystine concentration < 250 mg/L

AND

- ❑ Improvement/reduction in cystine crystalluria observed and documented (**follow up chart notes MUST be attached to request**)

Medication being provided by Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.